MYNZ Mainz Biomed
- 0.322
- -0.014-4.02%
Mainz Biomed News
Express News | Mainz Biomed Launches Improvements To ColoAlert
Mainz Biomed Launches Enhanced ColoAlert With Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test | NASDAQ:MYNZ
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
Top Premarket Decliners
Mainz Biomed Seeks FDA Breakthrough Device Status for Colorectal Cancer Test
Top Premarket Gainers
Express News | Mainz Biomed Shares Are Trading Higher After the Company Announced the Submission for FDA Breakthrough Device Designation for Its CRC Screening Test
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for Its Next Generation CRC Screening Test
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
MRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
Express News | Mainz Biomed Achieves Key Milestones In First Half Of 2024; Presents Leading Study Results, Secures Strategic Partnerships, And Prepares For FDA Pre-Market Approval And U.S. Go-To-Market Strategy For ColoAlert
Press Release: Mainz Biomed Provides Half Year 2024 Corporate Update
Mainz Biomed Provides Half Year 2024 Corporate Update
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Express News | Mainz Biomed NV : Jonestrading Cuts Target Price to $4 From $8
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
JonesTrading Maintains Mainz Biomed(MYNZ.US) With Buy Rating, Cuts Target Price to $4
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Analysis
Price Target
No Data
